Ipnolor

Lormetazepam, the active ingredient in Ipnolor, is a benzodiazepine presented as an oral formulation for oral use. It is prescribed to manage insomnia in adult patients who have difficulty initiating or maintaining sleep and may improve overall sleep quality under medical supervision. The medication is intended for short‑term therapy.

GNH USA supplies Ipnolor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across EU and global markets.

Lormetazepam is a benzodiazepine hypnotic used in the management of sleep disorders.

Insomnia: facilitates sleep onset and reduces nocturnal awakenings in adults.

Lormetazepam may cause a range of adverse reactions. The frequency and severity vary among individuals.

Common Side Effects: - Drowsiness - Dizziness - Headache - Fatigue - Impaired coordination - Memory impairment

Serious or Rare Side Effects: - Respiratory depression - Severe allergic reaction (anaphylaxis) - Paradoxical agitation or aggression - Dependence and withdrawal syndrome - Depression or suicidal thoughts - Seizures on abrupt discontinuation

Before prescribing Ipnolor, clinicians should evaluate patient history and potential risks. - Assess sleep duration: limit use to short‑term periods to avoid tolerance. - Evaluate respiratory function: avoid in patients with severe respiratory insufficiency. - Review concomitant CNS depressants: monitor for additive sedation. - Consider hepatic impairment: dose adjustment may be required. - Store at ambient temperature (below 25°C): keep in the original pack, protect from moisture and light.

Lormetazepam can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other CNS depressants (e.g., opioids, barbiturates): risk of profound sedation and respiratory depression. - Alcohol: additive CNS depression leading to impaired psychomotor function. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - CNS stimulants (e.g., caffeine, modafinil): may counteract hypnotic efficacy. - Antidepressants (e.g., SSRIs): may require dose adjustment and monitoring for enhanced sedation.